Panagiota Filippou, PhD

img-1
Panagiota Filippou, PhD Senior Lecturer in Biomedical Sciences, School of Health & Life Sciences, Teesside University, United Kingdom
img-2
Panagiota Filippou, PhD Senior Lecturer in Biomedical Sciences, School of Health & Life Sciences, Teesside University, United Kingdom

Panagiota Filippou, PhD
Senior Lecturer in Biomedical Sciences,
School of Health & Life Sciences,
Teesside University, United Kingdom

Dr Panagiota Filippou is currently a Senior Lecturer in Biomedical Sciences and a Course Leader of the MSc in Cancer and Molecular Diagnostics at Teesside University, United Kingdom. She obtained her PhD in Biochemistry from Aristotle University of Thessaloniki, Greece. Her most recent post-doctoral work was performed at the University Health Network, Mount Sinai hospital and University of Toronto, Toronto, ON, Canada, focusing on the cancer biomarker field using bioanalytical approaches. Her main research interests include the cancer biomarker discovery for early diagnosis, prediction of prognosis and therapeutic monitoring, and the identification of novel bioactive molecules and therapeutic targets in cancer therapeutics. Her translational research laboratory focuses on the identification of novel proteins, including cytokines, and other biomolecular signatures as cancer biomarkers in diagnostics for brain cancer and other cancers. Moreover, her group is searching for the biochemical pathways and mechanisms of carcinogenesis and tumor progression, thus deciphering opportunities for therapeutic intervention. To do this, a variety of molecular, biochemical, and analytical techniques combined with bioinformatic approaches are used. Dr Filippou has published in several peer-reviewed journals and received awards and scholarships of excellence.  She is a member of the European Association for Cancer Research, American Association for Cancer Research, the Biochemical Society, Metastasis Research Society, and a fellow of the Institute of Biomedical Sciences. She is an editorial board member in BMC Cancer and serves as an associate editor in Frontiers in Oncology and guest editor in Cancers and Molecular and Cellular Oncology.